A novel study demonstrates that using nanoparticles to deliver osteoarthritis drugs to the knee joint could help increase the retention of the drug in the knee cavity, and therefore reduce the frequency of injections patients must receive. This research was presented Oct. 23 - 27 at the 2011 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition in Washington, D.C.

Osteoarthritis affects 30 million Americans and is the most common joint disorder. It is projected to affect more than 20 percent of the U.S. population by 2025. Aging, obesity and joint injury can lead to osteoarthritis, which is characterized by progressive erosion of articular cartilage (cartilage that covers the bones). The disease can occur in all joints, most often the knees, hips, hands and spine, and currently there are no pharmacological treatments that halt the disease progression. For large joints, a drug could be injected into the joint to help limit potential side effects, like pain. A significant challenge in treating osteoarthritis this way is the short duration the medicine stays in the affected joint after injection.

Lead researcher Michael Morgen, Ph.D., and his colleagues from Bend Research and Pfizer propose to address this challenge with injectable nanoparticles that help retain osteoarthritis drugs in the knee joint. Test results show that 70 percent of the drug nanoparticles remain in the knee cavity after one week. In contrast, for most current formulations, the drug disperses within one to two days.

In this new process, positively charged nanoparticles carrying a drug attach to the negatively charged, naturally occurring molecules in the knee to form a gel. This gel acts as a depot that slows drug escape from the knee cavity.

"Current delivery methods do not maintain the drug in the knee for very long, which limits the effectiveness of therapeutic agents," said Dr. Morgen. "We hope that this type of sustained release technology, when used with current or new osteoarthritis drugs, will allow patients to be effectively treated with drug injections every three months instead of once a week."

  • Additional
  • References
  • Citations

A novel study demonstrates that using nanoparticles to deliver osteoarthritis drugs to the knee joint could help increase the retention of the drug in the knee cavity, and therefore reduce the frequency of injections patients must receive. This research was presented Oct. 23 - 27 at the 2011 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition in Washington, D.C.

Osteoarthritis affects 30 million Americans and is the most common joint disorder. It is projected to affect more than 20 percent of the U.S. population by 2025. Aging, obesity and joint injury can lead to osteoarthritis, which is characterized by progressive erosion of articular cartilage (cartilage that covers the bones). The disease can occur in all joints, most often the knees, hips, hands and spine, and currently there are no pharmacological treatments that halt the disease progression. For large joints, a drug could be injected into the joint to help limit potential side effects, like pain. A significant challenge in treating osteoarthritis this way is the short duration the medicine stays in the affected joint after injection.

Lead researcher Michael Morgen, Ph.D., and his colleagues from Bend Research and Pfizer propose to address this challenge with injectable nanoparticles that help retain osteoarthritis drugs in the knee joint. Test results show that 70 percent of the drug nanoparticles remain in the knee cavity after one week. In contrast, for most current formulations, the drug disperses within one to two days.

In this new process, positively charged nanoparticles carrying a drug attach to the negatively charged, naturally occurring molecules in the knee to form a gel. This gel acts as a depot that slows drug escape from the knee cavity.

"Current delivery methods do not maintain the drug in the knee for very long, which limits the effectiveness of therapeutic agents," said Dr. Morgen. "We hope that this type of sustained release technology, when used with current or new osteoarthritis drugs, will allow patients to be effectively treated with drug injections every three months instead of once a week."

  • Additional
  • References
  • Citations
She looked so relaxed, that I could imagine what it felt like to lie there myself. I'll find someone to give it to. Maybe it's because I spent a lot of time with my grandmother and her house was full of them.The painting that has touched me the most features a sad little girl and is called A Letter From My Mother. She favors animal prints, and I found one of a woman reclining in a hammock. It's too bad my parents didn't let her play football with the boys and I used to tease her relentlessly and pull her pigtails whenever I got the chance.There is a subcategory of folk art paintings that depict the world of black Americans. It's of a swamp house on a bayou and has a Louisiana feel to it. I saw a painting he did of.....

A significant challenge in treating osteoarthritis this way is the short duration the medicine stays in the affected joint after injection.Osteoarthritis affects 30 million Americans and is the most common joint disorder."Current delivery methods do not maintain the drug in the knee cavity, and therefore reduce the frequency of injections patients must receive.In this new process, positively charged nanoparticles carrying a drug attach to the negatively charged, naturally occurring molecules in the knee to form a gel. In contrast, for most current formulations, the drug disperses within one to two days. For large joints, a drug could be injected into the joint to help limit potential side effects, like pain." Additional References Citations . 23 - 27 at the 2011 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition in Washington, D. The disease can occur in all joints, most often the knees, hips, hands and spine, and currently there are no pharmacological treatments that halt the disease progression., and his colleagues from Bend Research and Pfizer propose to address this challenge with injectable nanoparticles that help retain osteoarthritis drugs in the knee joint. The disease can occur in all joints, most often the knees, hips, hands and spine, and currently there are no pharmacological treatments that halt the disease progression., and his colleagues from Bend Research and Pfizer propose to address this challenge with injectable nanoparticles that help retain osteoarthritis drugs in the knee joint. The disease can occur in all joints, most often the knees, hips, hands and spine, and currently there are no pharmacological treatments that halt the disease progression., and his colleagues from Bend Research and Pfizer propose to address this challenge with injectable nanoparticles that help retain osteoarthritis drugs in the knee joint. The disease My sister also shares my love for folk art. It's called Alligator Fisher and I'm thinking about getting because it reminds me of my cajun heritage, most of my family is from Louisiana.One of the most famous American artists is Thomas Chambers.There is a subcategory of folk art paintings that depict the world of black Americans. Now we're very close. When she died, she left me the painting and it hangs in a place of honor over my fireplace mantle. Maybe it's because I spent a lot of time with my grandmother and her house was full of them. One of my favorites that she had was done by John Roeder. It's called First Trolley to Van Nuys and shows the center of a town filled with people. She favors animal prints, and I found one that depicts leopards and gave it to her for her birthday. It's too bad my parents didn't let her play football with us. I personally don't have any of these in my collection, since I like to collect pieces that I can relate to. It's of a swamp house on a bayou and has a Louisiana feel to it.The painting that has touched me the

rthritis drugs athritis drugs arhritis drugs artritis drugs arthitis drugs arthrtis drugs arthriis drugs arthrits drugs arthriti drugs arthritis rugs arthritis dugs arthritis drgs arthritis drus arthritis drug srthritis drugs aethritis drugs atthritis drugs arrhritis drugs aryhritis drugs artgritis drugs artjritis drugs artheitis drugs arthtitis drugs arthrutis drugs arthrotis drugs arthriris drugs arthriyis drugs arthritus drugs arthritos drugs arthritia drugs arthritid drugs arthritis srugs arthritis frugs arthritis deugs arthritis dtugs arthritis drygs arthritis drigs arthritis drufs arthritis druhs arthritis druga arthritis drugd rathritis drugs atrhritis drugs arhtritis drugs artrhitis drugs arthirtis drugs arthrtiis drugs arthriits drugs arthritsi drugs arthriti sdrugs arthritis rdugs arthritis durgs arthritis drgus arthritis drusg arthritis drug aarthritis drugs arrthritis drugs artthritis drugs arthhritis drugs arthrritis drugs arthriitis drugs arthrittis drugs arthritiis drugs arthritiss drugs arthritis ddrugs arthritis drrugs arthritis druugs arthritis druggs arthritis drugss
A novel study demonstrates that using nanoparticles to deliver osteoarthritis drugs to the knee joint could help increase the retention of the drug in the knee cavity, and therefore reduce the frequency of injections patients must receive. This research was presented Oct. 23 - 27 at the 2011 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition in Washington, D.C.

Osteoarthritis affects 30 million Americans and is the most common joint disorder. It is projected to affect more than 20 percent of the U.S. population by 2025. Aging, obesity and joint injury can lead to osteoarthritis, which is characterized by progressive erosion of articular cartilage (cartilage that covers the bones). The disease can occur in all joints, most often the knees, hips, hands and spine, and currently there are no pharmacological treatments that halt the disease progression. For large joints, a drug could be injected into the joint to help limit potential side effects, like pain. A significant challenge in treating osteoarthritis this way is the short duration the medicine stays in the affected joint after injection.

Lead researcher Michael Morgen, Ph.D., and his colleagues from Bend Research and Pfizer propose to address this challenge with injectable nanoparticles that help retain osteoarthritis drugs in the knee joint. Test results show that 70 percent of the drug nanoparticles remain in the knee cavity after one week. In contrast, for most current formulations, the drug disperses within one to two days.

In this new process, positively charged nanoparticles carrying a drug attach to the negatively charged, naturally occurring molecules in the knee to form a gel. This gel acts as a depot that slows drug escape from the knee cavity.

"Current delivery methods do not maintain the drug in the knee for very long, which limits the effectiveness of therapeutic agents," said Dr. Morgen. "We hope that this type of sustained release technology, when used with current or new osteoarthritis drugs, will allow patients to be effectively treated with drug injections every three months instead of once a week."

  • Additional
  • References
  • Citations

A novel study demonstrates that using nanoparticles to deliver osteoarthritis drugs to the knee joint could help increase the retention of the drug in the knee cavity, and therefore reduce the frequency of injections patients must receive. This research was presented Oct. 23 - 27 at the 2011 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition in Washington, D.C.

Osteoarthritis affects 30 million Americans and is the most common joint disorder. It is projected to affect more than 20 percent of the U.S. population by 2025. Aging, obesity and joint injury can lead to osteoarthritis, which is characterized by progressive erosion of articular cartilage (cartilage that covers the bones). The disease can occur in all joints, most often the knees, hips, hands and spine, and currently there are no pharmacological treatments that halt the disease progression. For large joints, a drug could be injected into the joint to help limit potential side effects, like pain. A significant challenge in treating osteoarthritis this way is the short duration the medicine stays in the affected joint after injection.

Lead researcher Michael Morgen, Ph.D., and his colleagues from Bend Research and Pfizer propose to address this challenge with injectable nanoparticles that help retain osteoarthritis drugs in the knee joint. Test results show that 70 percent of the drug nanoparticles remain in the knee cavity after one week. In contrast, for most current formulations, the drug disperses within one to two days.

In this new process, positively charged nanoparticles carrying a drug attach to the negatively charged, naturally occurring molecules in the knee to form a gel. This gel acts as a depot that slows drug escape from the knee cavity.

"Current delivery methods do not maintain the drug in the knee for very long, which limits the effectiveness of therapeutic agents," said Dr. Morgen. "We hope that this type of sustained release technology, when used with current or new osteoarthritis drugs, will allow patients to be effectively treated with drug injections every three months instead of once a week."

  • Additional
  • References
  • Citations